Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15427005 | 0.85 | SMN1; SMN2 (0.63) | LMNATSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30162895 | 0.85 | SMN1; SMN2 (0.63) | LMNATSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15427002 | 0.83 | LMNA (0.54) | LMNATSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15427060 | 0.75 | SMN1; SMN2 (0.60) | LMNATSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15427135 | 0.74 | TSHR (0.68) | LMNATSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL15427014 | 0.73 | SMN1; SMN2 (0.65) | LMNATSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10280347 | 0.73 | KMT2A (0.70) | LMNASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL15426992 | 0.72 | MAPT (0.74) | LMNATSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL19270406 | 0.72 | ALDH1A1 (0.47) | LMNATSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15427010 | 0.72 | TP53 (0.67) | LMNAMEN1KMT2AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2016-02-25 | — | — | US | disclosed |
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2016-02-25 | — | — | US | disclosed |
| US-9212209-B2 | Screening methods for spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212209-B2 | Screening methods for spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2014-07-10 | — | — | US | disclosed |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2014-07-10 | — | — | US | disclosed |
| WO-2014012050-A2 | COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, MTPN | LMNA 278/4885TSHR 4716/4885SMN1; SMN2 1/4885 |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MYOF, MTPN | LMNA 148/4885TSHR 4677/4885SMN1; SMN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.